Zymeworks (ZYME) Total Non-Current Liabilities (2021 - 2026)
Zymeworks (ZYME) reported Total Non-Current Liabilities of $314.3 million for Q1 2026, up 215.3% on a YoY basis from $99.7 million in Q1 2025, and up 304.32% sequentially from $77.7 million in Q4 2025.
Zymeworks (ZYME) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Total Non-Current Liabilities data on file, last reported at $314.3 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 215.3% year-over-year to $314.3 million; the trailing twelve-month figure through Mar 2026 stood at $314.3 million (up 215.3% YoY), and the FY2025 full-year result was $77.7 million, down 37.0% from the prior year.
- Total Non-Current Liabilities improved to $314.3 million in Q1 2026, from $77.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $314.3 million in Q1 2026 to a low of $73.1 million in Q2 2025.
- A 5-year average of $126.5 million and a median of $117.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities sank 37.0% in 2025 and surged 215.3% in 2026, its largest moves.
- Tracing ZYME's Total Non-Current Liabilities over 5 years: stood at $154.1 million in 2022, then retreated by 25.79% to $114.4 million in 2023, then increased by 7.89% to $123.4 million in 2024, then slumped by 37.0% to $77.7 million in 2025, then jumped by 304.32% to $314.3 million in 2026.
- Business Quant data shows ZYME's Total Non-Current Liabilities at $314.3 million in Q1 2026, $77.7 million in Q4 2025, and $76.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | 314.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 314.35 Mn |
| Dec 31, 2025 | 77.75 Mn |
| Sep 30, 2025 | 76.93 Mn |
| Jun 30, 2025 | 73.05 Mn |
| Mar 31, 2025 | 99.70 Mn |
| Dec 31, 2024 | 123.40 Mn |
| Sep 30, 2024 | 119.25 Mn |
| Jun 30, 2024 | 108.24 Mn |
| Mar 31, 2024 | 114.16 Mn |
| Dec 31, 2023 | 114.37 Mn |
| Sep 30, 2023 | 131.73 Mn |
| Jun 30, 2023 | 149.54 Mn |
| Mar 31, 2023 | 123.61 Mn |
| Dec 31, 2022 | 154.13 Mn |
| Sep 30, 2022 | 117.57 Mn |
| Dec 31, 2021 | 137.29 Mn |